Lexeo Therapeutics (LXEO) Insider Cooperstone Buys 35,000 Shares

Brenda Cooperstone Purchases Lexeo Therapeutics Shares

Brenda Cooperstone picked up 35,000 shares of Lexeo Therapeutics, Inc. (NasdaqGM: LXEO) on June 25, 2026. This transaction fits into a broader pattern of insider buying at the biotechnology company, matching parallel purchases made by other insiders on the exact same date. While prior filings showed large holders like Avoro Capital reducing positions earlier in the year, leadership team members have stepped in to acquire fresh equity.

Insider Buying and Selling at Lexeo Therapeutics, Inc.

The June 25, 2026 transaction included matching purchases from other key figures within the organization. Tolga Tanguler acquired 35,000 shares on the same date, while Agger Mette Kirstine also picked up 35,000 shares. These clustered purchases by Cooperstone, Tanguler, and Mette Kirstine show multiple insiders adding to their personal stakes on a single day.

Lexeo Therapeutics Stock Price and Market Standing

Lexeo Therapeutics shares traded at a spot price of $4.81 on Tuesday. The equity has moved between a 52-week low of $3.99 and a 52-week high of $10.99. With a market capitalization of $334.7 million, the clinical-stage genetic medicine developer continues to draw attention from both corporate insiders and market analysts following recent share price shifts.

Analysts Set New Price Targets

Wall Street firms continue to follow the clinical-stage company closely, updating their outlooks alongside these insider moves. On June 25, 2026, JP Morgan maintained an overweight rating while adjusting its price target from $12.00 to $9.00. Later, on September 23, 2026, Leerink Partners maintained its outperform rating on the stock with a price target of $15.00. Across the broader analyst community covering the firm, ten experts carry a consensus target price of $20.30, with individual targets ranging from a low of $9.00 to a high of $30.00.

Background on Lexeo Therapeutics

Headquartered in New York, New York, Lexeo Therapeutics is a clinical-stage genetic medicine company focused on addressing hereditary and acquired conditions with high unmet needs. The organization employs 63 people and develops gene therapy candidates targeting conditions such as Friedreich ataxia cardiomyopathy, Alzheimer's disease, and inherited cardiac muscle disorders. Its pipeline work relies on specialized AAV vectors to deliver functional genes directly to human cardiac and neural cells.

What to Watch Next for LXEO

Investors will look toward the company's next financial results release scheduled for November 4, 2026, for updates on its clinical trials and upcoming milestones. Market participants should also monitor future SEC filings to see whether insiders continue adding to their holdings as these pipeline programs advance through clinical phases.